ASKG 315
Alternative Names: ASKG-315Latest Information Update: 29 Sep 2022
At a glance
- Originator AskGene Pharma
- Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin-15 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 29 Sep 2022 AskGene Pharma in collaboration with Jiangsu Aosaikang Pharmaceutical plans a phase I for Solid tumours (Late-stage disease, Refractory Metastatic disease, Second-line therapy or greater) in October 2022 (IV, Infusion) (NCT05554666)
- 24 Aug 2022 AskGene Pharma in collaboration with Jiangsu Aosaikang Pharmaceutical plans a phase I trial for Solid tumours (Late-stage disease, Second-line or greater, Refractory metastatic disease, Monotherapy, Combination therapy) in September 2022 (IV) (Injection) (NCT05509985)
- 02 Jun 2021 Preclinical trials in Cancer in USA (unspecified route)